机构：[1]School of Medicine, University of Electronic Science and Technology of China, Chengdu, China四川省人民医院[2]Department of Nephrology, Sichuan Academy of Medical Science and Sichuan Provincial People’s Hospital, Sichuan Renal Disease Clinical Research Center, University of Electronic Science and Technology of China, Chengdu, China四川省人民医院[3]Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China四川省人民医院[4]Reproductive & Women-Children Hospital, School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China[5]Department of Cardiac Surgery, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Guangdong Cardiovascular Institute, Southern Medical University, Guangzhou 510100, Guangdong, China广东省人民医院[6]Department of Nephrology, Osaka University Graduate School of Medicine, Osaka, Japan[7]Renal Department and Nephrology Institute, School of Medicine, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Sichuan Clinical Research Center for Kidney Diseases, Chengdu, China四川省人民医院
Kidney disease is a progressive and irreversible condition in which immunity is a contributing factor that endangers human health. It is widely acknowledged that macrophages play a significant role in developing and causing numerous kidney diseases. The increasing focus on the mechanism by which macrophages express apoptosis inhibitor of macrophages (AIM) in renal diseases has been observed. AIM is an apoptosis inhibitor that stops different things that cause apoptosis from working. This keeps AIM-bound cell types alive. Notably, the maintenance of immune cell viability regulates immunity. As our investigation progressed, we concluded that AIM has two sides when it comes to renal diseases. AIM can modulate renal phagocytosis, expedite the elimination of renal tubular cell fragments, and mitigate tissue injury. AIM can additionally exacerbate the development of renal fibrosis and kidney disease by prolonging inflammation. IgA nephropathy (IgAN) may also worsen faster if more protein is in the urine. This is because IgA and immunoglobulin M are found together and expressed. In the review, we provide a comprehensive overview of prior research and concentrate on the impacts of AIM on diverse subcategories of nephropathies. We discovered that AIM is closely associated with renal diseases by playing a positive or negative role in the onset, progression, or cure of kidney disease. AIM is thus a potentially effective therapeutic target for kidney diseases.
基金：
The work was supported by Foundation of Key R&D plan of Sichuan Province
(2019YFS0538); National Natural Science Foundation of China (82200810).
The project of 2020 High-level Overseas Chinese Talent Returning Funding;
Foundation of Applied Basic Research Project of Sichuan Provincial Science
and Technology (2020YJ0179); Youth Fund of Natural Science Foundation of
Sichuan Provincial Department of Science and Technology (23NSFSC3885);
Foundation for Young Talent Fund of Sichuan Provincial People’s Hospital
(2022QN02); Discipline construction fund of Sichuan Provincial People’s
Hospital.
第一作者机构：[1]School of Medicine, University of Electronic Science and Technology of China, Chengdu, China[2]Department of Nephrology, Sichuan Academy of Medical Science and Sichuan Provincial People’s Hospital, Sichuan Renal Disease Clinical Research Center, University of Electronic Science and Technology of China, Chengdu, China[3]Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China
共同第一作者：
通讯作者：
通讯机构：[2]Department of Nephrology, Sichuan Academy of Medical Science and Sichuan Provincial People’s Hospital, Sichuan Renal Disease Clinical Research Center, University of Electronic Science and Technology of China, Chengdu, China[3]Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China[7]Renal Department and Nephrology Institute, School of Medicine, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Sichuan Clinical Research Center for Kidney Diseases, Chengdu, China
推荐引用方式(GB/T 7714)：
Cao Yixia,Hu Boyan,Fan Yunhe,et al.The effects of apoptosis inhibitor of macrophage in kidney diseases[J].EUROPEAN JOURNAL OF MEDICAL RESEARCH.2024,29(1):doi:10.1186/s40001-023-01597-3.
APA：
Cao, Yixia,Hu, Boyan,Fan, Yunhe,Wang, Wei,Chi, Mingxuan...&Liu, Chi.(2024).The effects of apoptosis inhibitor of macrophage in kidney diseases.EUROPEAN JOURNAL OF MEDICAL RESEARCH,29,(1)
MLA：
Cao, Yixia,et al."The effects of apoptosis inhibitor of macrophage in kidney diseases".EUROPEAN JOURNAL OF MEDICAL RESEARCH 29..1(2024)
